CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention Consensus from the 5th European Bifurcation Club meeting Intravascular ultrasound predictors for edge restenosis after newer generation drug-eluting stent implantation Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure Timing of intervention in asymptomatic patients with valvular heart disease

Original ResearchEpub January 12, 2018

JOURNAL:Am J Cardiol. Article Link

Prognostic Significance of Complex Ventricular Arrhythmias Complicating ST-Segment Elevation Myocardial Infarction

omasz Podolecki; Radoslaw Lenarczyk, Jacek Kowalczyk et al. Keywords: ventricular fibrillation, ventricular tachycardia, acute myocardial infarction, percutaneous coronary intervention

ABSTRACT

The aim of the study was to assess the clinical significance of complex ventricular arrhythmias (VAs) (sustained ventricular tachycardia (sVT) and ventricular fibrillation (VF)) in patients with ST-segment elevation myocardial infarction (STEMI) depending on timing of arrhythmia. We analyzed 4, 363 consecutive STEMI-patients treated invasively between 2004 and 2014. The median follow-up was 69.6 months (range: 0–139.8 months). The study population was divided into 2 main groups: VA Group encompassed 476 (10.91 %) patients with VAs, whereas 3887 (89.09 %) subjects without VT/VF were included into the Control Group. Among VA-population, pre-reperfusion VA (34.24%; n=163) was the most common arrhythmia, whereas reperfusion-induced, early post-reperfusion and late post-reperfusion VAs were diagnosed in: 103 (21.64 %), 103 (21.64 %) and 107 (22.48 %) patients, respectively. Every type of sVT/VF complicating STEMI portended significantly worse in-hospital prognosis, however a late onset arrhythmia was associated with the highest (over 5-fold) and reperfusion-induced VA with the lowest (less than 3-fold) increase in mortality risk compared to the Control Group. On the contrary, long-term mortality was significantly increased only in subjects with late post-reperfusion and pre-reperfusion VAs compared to VA-free population (43.93% and 36.81%, respectively vs. 22.58%; p<0.001). Apart from cardiogenic shock on admission, late post-reperfusion (HR 3.39) and pre-reperfusion VAs (HR 2.76) were the strongest independent predictors of death in the analyzed population. In conclusion, one in 10 patients with STEMI treated invasively was affected by sVT/VF. The clinical impact of VAs was strongly dependent on timing of arrhythmia.